Resection of the Primary Tumor Prior to Peptide Receptor Radionuclide Therapy Improves Treatment Response and Progression-free Survival in Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases

#1336

Introduction: A low burden of disease represents an independent favorable prognostic factor of response to peptide receptor radionuclide therapy (PRRT) in patients affected by gastro-entero-pancreatic neuroendocrine tumors. However it is not clear whether this is due to a lower diffusion of the disease or thanks to debulking surgery

Aim(s): To ascertain whether resection of the primary tumor prior to PRRT could have an impact on response to PRRT and on progression-free survival in patients with G1-G2 metastatic pancreatic neuroendocrine tumors (PNETs)

Materials and methods: From 1996 to 2013 those patients diagnosed with G1-G2 pancreatic neuroendocrine tumor (PNET), and synchronous unresectable liver metastases who were eligible to receive upfront PRRT were included in the study. Two groups of comparison were identified: those submitted for primary tumor resection before PRRT and those who were not

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Bertani E

Authors: Bertani E, Fazio N, Grana C, Bodei L, Funicelli L,

Keywords: PNET, PRRT, debulking surgery, PFS,